Related Experiment Video
Updated: May 12, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Development of the hepatitis E vaccine: from bench to field
Jun Zhang1, James WaiKuo Shih, Ting Wu
1National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, People's Republic of China.
Abstract:
Along with the improvement of diagnostic techniques, hepatitis E has attracted increasing awareness in recent years. Hepatitis E virus infection leads to high mortality in pregnant women and patients with underlying liver disease. Several hepatitis E vaccine candidates have been designed and have proved their efficacy in animal models; two candidates have successfully undergone clinical trials. Having proved safe and effective in a large phase III trials, an Escherichia coli expressed particulate protein, HEV 239, has been registered in China and is now available for use in China.
Related Concept Videos
Vaccine Production
Viral Hepatitis I: Introduction
Hepatitis
Vaccinations
Preclinical Development: Overview

